Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.22 Insider Own34.86% Shs Outstand46.25M Perf Week-5.05%
Market Cap2.36B Forward P/E- EPS next Y-1.67 Insider Trans0.00% Shs Float33.78M Perf Month-6.94%
Income-55.59M PEG- EPS next Q-0.31 Inst Own73.03% Short Float9.77% Perf Quarter246.19%
Sales7.29M P/S323.55 EPS this Y-9.34% Inst Trans1.30% Short Ratio2.84 Perf Half Y424.08%
Book/sh12.65 P/B3.60 EPS next Y-15.96% ROA-10.67% Short Interest3.30M Perf Year240.49%
Cash/sh12.57 P/C3.62 EPS next 5Y- ROE-11.50% 52W Range5.65 - 65.60 Perf YTD323.95%
Dividend Est.- P/FCF- EPS past 5Y-92.62% ROI-8.20% 52W High-30.66% Beta3.62
Dividend TTM- Quick Ratio62.09 Sales past 5Y32.66% Gross Margin72.09% 52W Low705.13% ATR (14)4.01
Dividend Ex-Date- Current Ratio62.09 EPS Y/Y TTM24.13% Oper. Margin-999.85% RSI (14)41.68 Volatility4.81% 8.24%
Employees64 Debt/Eq0.04 Sales Y/Y TTM-19.67% Profit Margin-762.92% Recom1.00 Target Price64.75
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q28.01% Payout- Rel Volume0.76 Prev Close47.99
Sales Surprise42.50% EPS Surprise9.42% Sales Q/Q-38.87% EarningsMay 07 AMC Avg Volume1.16M Price45.49
SMA20-14.08% SMA50-1.40% SMA200123.54% Trades Volume878,698 Change-5.21%
Date Action Analyst Rating Change Price Target Change
Mar-21-24Initiated BTIG Research Buy $62
Mar-20-24Initiated Cantor Fitzgerald Overweight $100
Apr-06-23Initiated Wedbush Outperform $24
Nov-14-22Initiated William Blair Outperform
May-17-24 04:12PM
May-09-24 10:26AM
May-08-24 09:06AM
May-07-24 10:56PM
04:01PM Loading…
Apr-30-24 08:50AM
Apr-25-24 11:28AM
Apr-17-24 01:12PM
Apr-16-24 01:19PM
Apr-15-24 12:54PM
Apr-12-24 08:50AM
Apr-11-24 04:19PM
09:55AM Loading…
Apr-10-24 06:39PM
Apr-08-24 09:35AM
Mar-28-24 12:00PM
Mar-22-24 09:55AM
Mar-20-24 03:44PM
Mar-15-24 10:53AM
Mar-08-24 04:31PM
Mar-02-24 06:56AM
Mar-01-24 08:50AM
Feb-29-24 01:22AM
Feb-27-24 05:00PM
04:04PM Loading…
Feb-26-24 04:05PM
Feb-21-24 02:39AM
Feb-20-24 08:00AM
Jan-08-24 09:00AM
Dec-01-23 09:55AM
Nov-15-23 09:55AM
Nov-10-23 09:35AM
Nov-07-23 04:01PM
Aug-17-23 09:56AM
Aug-10-23 09:55AM
Aug-08-23 05:40PM
Jul-20-23 12:00PM
Jul-17-23 08:45AM
Jun-05-23 04:35PM
May-09-23 05:15PM
May-02-23 10:01AM
Apr-24-23 04:01PM
Apr-20-23 04:01PM
Apr-05-23 10:22AM
Mar-15-23 11:44AM
Mar-10-23 04:01PM
Feb-14-23 12:00PM
Feb-10-23 05:30AM
Jan-10-23 12:00PM
Dec-27-22 09:00AM
Nov-23-22 09:55AM
Nov-22-22 06:00AM
Nov-21-22 12:22PM
Nov-16-22 06:15AM
Nov-10-22 04:01PM
Oct-27-22 09:18AM
Oct-22-22 10:01AM
Oct-12-22 09:00AM
Sep-23-22 06:00AM
Sep-22-22 06:00AM
Aug-31-22 09:00AM
Aug-09-22 04:01PM
Jul-04-22 08:43AM
Jun-02-22 08:00AM
May-31-22 08:00AM
May-20-22 07:37AM
May-10-22 04:01PM
Apr-26-22 08:30AM
Mar-18-22 04:01PM
Mar-01-22 08:01AM
Jan-05-22 04:01PM
Dec-11-21 08:44AM
Nov-25-21 07:35AM
Nov-09-21 04:01PM
Nov-08-21 08:00AM
Sep-12-21 10:40AM
Sep-09-21 04:01PM
Sep-07-21 04:01PM
Jul-19-21 08:00AM
Jun-15-21 04:01PM
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Avalon Ventures XI, L.P.10% OwnerNov 13 '23Buy5.87849,8544,988,643849,854Nov 13 07:11 PM
Reardon TigheActing Chief Financial OfficerNov 13 '23Buy5.87849,8544,988,643849,854Nov 15 04:48 PM
Lichter JayDirectorNov 13 '23Buy5.87849,8544,988,643849,854Nov 15 04:46 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 19 '23Buy12.46495,0086,167,8008,117,246Jul 21 04:31 PM